EGFR and non-small cell lung carcinoma: For instance, non-small cell lung cancers (NSCLCs) harboring activating EGFR mutations frequently develop the T790M substitution upon prolonged exposure to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs), drastically diminishing drug binding affinity [159].